Search hospitals > Quebec > MONTREAL

Jewish General Hospital

Claim this profile
MONTREAL, Quebec H3T 1E2
Global Leader in Breast Cancer
Global Leader in Prostate Cancer
Conducts research for Parotid Gland Cancer
Conducts research for Prostatic Neoplasm
Conducts research for Lymphoma
527 reported clinical trials
31 medical researchers
Photo of Jewish General Hospital in MONTREALPhoto of Jewish General Hospital in MONTREALPhoto of Jewish General Hospital in MONTREAL

Summary

Jewish General Hospital is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Breast Cancer, Prostate Cancer, Parotid Gland Cancer, Prostatic Neoplasm, Lymphoma and other specialties. Jewish General Hospital is involved with conducting 527 clinical trials across 596 conditions. There are 31 research doctors associated with this hospital, such as Cristiano Ferrario, MD, Dr. Tamim Niazi, MDCM, Petr Kavan, Dr, and Wilson Miller.

Area of expertise

1Breast Cancer
Global Leader
Jewish General Hospital has run 98 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
Stage III
2Prostate Cancer
Global Leader
Jewish General Hospital has run 39 trials for Prostate Cancer. Some of their research focus areas include:
Stage IV
metastatic
testosterone

Top PIs

Clinical Trials running at Jewish General Hospital

Breast Cancer
Multiple Myeloma
Prostate Cancer
Chronic Lymphocytic Leukemia
Lymphoma
Non-Small Cell Lung Cancer
Lung Cancer
Colorectal Cancer
Deep Vein Thrombosis
Plasma Cell Neoplasm
Image of trial facility.

Sacituzumab Govitecan

for Triple-Negative Breast Cancer

This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
Recruiting4 awards Phase 3
Image of trial facility.

sac-TMT + Pembrolizumab

for Breast Cancer

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sacituzumab tirumotecan plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment.
Recruiting2 awards Phase 35 criteria
Image of trial facility.

Sacituzumab Tirumotecan + Pembrolizumab

for Breast Cancer

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer. The primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) in all participants.
Recruiting2 awards Phase 33 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Jewish General Hospital?
Where is Jewish General Hospital located?
Who should I call to ask about financial aid or insurance network?
What insurance does Jewish General Hospital accept?
What awards or recognition has Jewish General Hospital received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security